Health Care [ 9/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.
The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette"guérin therapy.
Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 25 | -0.47 Decreased by -14.63% | -0.47 |
| May 15, 25 | -0.55 Decreased by -37.50% | -0.48 Decreased by -14.58% |
| Mar 24, 25 | -0.52 Increased by +7.14% | -0.44 Decreased by -18.18% |
| Nov 12, 24 | -0.42 Increased by +12.50% | -0.44 Increased by +4.55% |
| Aug 7, 24 | -0.41 Increased by +14.58% | -0.45 Increased by +8.89% |
| May 9, 24 | -0.40 Increased by +13.04% | -0.49 Increased by +18.37% |
| Mar 12, 24 | -0.56 Decreased by -1.82% | -0.41 Decreased by -36.59% |
| Nov 9, 23 | -0.48 Increased by +11.11% | -0.52 Increased by +7.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -27.02 M Decreased by -32.86% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -27.48 M Decreased by -39.47% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 1.24 M Decreased by -39.79% | -25.83 M Decreased by -16.73% | Decreased by -2.09 K% Decreased by -93.86% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -21.04 M Decreased by -13.67% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -20.34 M Decreased by -11.14% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 2.06 M Increased by +N/A% | -19.71 M Decreased by -29.99% | Decreased by -958.46% Decreased by N/A% |
| Dec 31, 23 | 2.06 M Increased by +N/A% | -22.13 M Increased by +47.07% | Decreased by -1.08 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -18.51 M Decreased by -17.56% | Decreased by N/A% Decreased by N/A% |